Tags : Robert von Rosen

Capital Markets

Walder Wyss advises Acton and VI Partners on a series

The Zurich-based Skribble, a specialist for electronic signatures, has completed a round of funding with an investment volume of EUR 10 million. The round is led by Acton Capital Partners from Munich, an international venture capital company that focuses on digital business models and sees strong revenue growth in Europe and North America. The Swiss […]

Deal & transactions

Walder Wyss on the acquisition of groupe.id by Elvaston

The groupe. id has been acquired by German private equity firm Elvaston Capital Management. Based in La Chaux-de-Fonds and also present in Yverdon-les-Bains, the groupe.id is a renowed Swiss provider of enterprise resource planning software solutions. Founded in 1982, the Swiss group develops and delivers technological services with high added value, especially in terms of […]

Deal & transactions

Walder Wyss on the sell of Magnolia to GENUI

Elvaston, an entrepreneur-led private equity firm, has sold its participation in Magnolia International to GENUI. The investment company has acquired a majority stake in Magnolia and will injects significant growth capital into the company. Magnolia is a Swiss based digital experience software company, developing and distributing a digital experience platform as well as a content […]

Deal & transactions

Cawood Scientific Limited acquires Innovative Environmental Services

Cawood Scientific Limited, the UK based independent provider of analytical testing and sampling services for land-based industries, has tripled the size of its research business through the acquisition of Innovative Environmental Services (IES), an independent contract research organisation (CRO) located near Basel, Switzerland.   Innovative Environmental Services (IES) services support the development, registration, and stewardship of pharmaceuticals, agrochemicals, biocides, and chemical products.  […]

Deal & transactions

Walder Wyss advised Dr. Wild & Co. on sale of

Walder Wyss acted as legal counsel to Dr. Wild & Co., the Swiss family-owned pharmaceutical manufacturer, on the sale of its Pharma business, including its product portfolio in Vitamin D and other well-known products, to Verfora an affiliate of Galenica Group (SIX Swiss Exchange: GALE), at the end of May 2021. On this transaction, the […]

Deal & transactions

Walder Wyss and VISCHER in the sale of NBE-Therapeutics to

Walder Wyss advises Boehringer Ingelheim. The team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured left) and Robert von Rosen (Partner, Corporate/M&A and Venture Capital). VISCHER advised NBE-Therapeutics and its shareholders in this transaction. The team was led by Matthias Staehelin (pictured right) with Vincent Reardon, Pauline Pfirter, Céderic Saladin (all Corporate) and Nadia Tarolli (Tax).